Information Provided By:
Fly News Breaks for May 18, 2017
INCY
May 18, 2017 | 06:28 EDT
JPMorgan analyst Cory Kasimov believes last night's abstracts for epacadostat demonstrate "consistent and compelling evidence" of efficacy across multiple tumor types, consistent with what Incyte has been telling with Street. The analyst is "encouraged" by emerging data and expect it will "restore positive sentiment" in the name and add to the company's perceived strategic value. He reiterates an Overweight rating on Incyte shares with a $149 price target.
News For INCY From the Last 2 Days
INCY
INCY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.